Abstract

BackgroundWe previously demonstrated a positive correlation with nursing home (NH) replacement and donepezil (DNP) administration on lifetime expectancy after the onset of Alzheimer’s disease (AD). However, the correlation with quality-adjusted life-year (QALY) remains to be elucidated, along with the additional impact of concomitant cerebrovascular disease (CVD). Based upon our recently reported health state utility values, we retrospectively analyzed the correlation with NH replacement and/or DNP administration on QALY and life expectancy in ‘pure’ AD (without CVD) and AD with CVD patients.MethodsAll outpatients at the Tajiri Clinic from 1999–2012 with available medical records and death certificates were included. The entry criteria were a dementia diagnosis (DSM-IV) and diagnoses of pure AD or AD with CVD (NINCDS-ADRDA), medical treatment for more than 3 months, and follow up to less than 1 year before death. The main outcomes were lifetime expectancy (months between the onset of dementia and death) and QALY.ResultsWe identified 390 subjects, of whom 275 had the diagnosis of dementia that met the entry criteria, including 67 pure AD, 33 AD with CVD, and 110 VaD patients. For the AD patients, 52 had taken DNP and 48 had not received the drug due to treatment prior to the introduction of DNP in 1999 in Japan. For the pure AD group, there were positive correlation between NH and DNP and QALY, as well as lifetime expectancy. As for the AD with CVD group, only a correlation between DNP and lifetime expectancy was noted, with no correlation with QALY.ConclusionsWe found positive correlations between DNP administration and NH replacement and lifetime expectancy and QALY after the onset of AD. However, concomitant CVD negated such a positive correlation with QALY. The findings suggest that QALY in AD is affected by CVD; thus, indicating the importance of CVD prevention.

Highlights

  • We previously demonstrated a positive correlation with nursing home (NH) replacement and donepezil (DNP) administration on lifetime expectancy after the onset of Alzheimer’s disease (AD)

  • We previously reported a positive impact of nursing home (NH) placement and DNP administration on lifetime expectancy after the onset of AD [6]

  • The correlation between DNP and lifetime expectancy in the AD without cerebrovascular disease (CVD) group (F = 4.704) in Table 1 may be influenced by the familywise error

Read more

Summary

Introduction

We previously demonstrated a positive correlation with nursing home (NH) replacement and donepezil (DNP) administration on lifetime expectancy after the onset of Alzheimer’s disease (AD). There are no curative drugs for Alzheimer’s disease (AD) at present; symptomatic drugs, such as cholinesterase inhibitors (ChEIs) can delay progression of the disease This effect, combined with psychosocial interventions, can increase the quality of life (QOL) [1]. These drugs administration can delay nursing home placement [2] and may reduce mortality for patients living in nursing homes [3] and in the community [4]. We previously reported a positive impact of nursing home (NH) placement and DNP administration on lifetime expectancy after the onset of AD [6]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call